Showing results (501-510 of 520) with videos related to

Sort By:
Pageof 52
Oncoimmunology|July 29, 2016
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinomaHans A Schlößer, Uta Drebber, Michael Kloth, et al.
Cancer Immunology Research|April 17, 2024
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating LymphocytesDavid König, Michael T Sandholzer, Sarp Uzun, et al.
Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Science Immunology|May 10, 2024
Nucleobase adducts bind MR1 and stimulate MR1-restricted T cellsAlessandro Vacchini, Andrew Chancellor, Qinmei Yang, et al.
Immunity|June 14, 2023
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesFelix Bayerl, Philippa Meiser, Sainitin Donakonda, et al.
Spine|April 12, 2024
Association Between Severity of Cervical Central Spinal Stenosis and Paraspinal Muscle Parameters in Patients Undergoing Anterior Cervical Discectomy and FusionThomas Caffard, Artine Arzani, Bruno Verna, et al.
Oncotarget|October 21, 2017
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibitionGongda Xue, Reto Kohler, Fengyuan Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Science Translational Medicine|November 2, 2022
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockadeMichal A Stanczak, Natalia Rodrigues Mantuano, Nicole Kirchhammer, et al.
Pageof 52